Cargando…
Biomarkers in phase I–II chemoprevention trials: lessons from the NCI experience
Early phase clinical trials are an essential component of chemopreventive drug development to identify signals of drug efficacy that can subsequently be explored definitively in phase III trials. Whereas phase I trials focus on safety and identification of optimal dose and schedule for cancer preven...
Autor principal: | Szabo, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664504/ https://www.ncbi.nlm.nih.gov/pubmed/26635903 http://dx.doi.org/10.3332/ecancer.2015.599 |
Ejemplares similares
-
The New NCI Precision Medicine Trials
por: Harris, Lyndsay N., et al.
Publicado: (2023) -
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
por: Flaherty, Keith T, et al.
Publicado: (2020) -
HLA class I and II genotype of the NCI-60 cell lines
por: Adams, Sharon, et al.
Publicado: (2005) -
Corrigendum to: The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Publicado: (2021) -
Report from an NCI Roundtable: Cancer Prevention in Primary Care
por: Samimi, Goli, et al.
Publicado: (2022)